Key player · Company profile
Bayer AG
Named as a key player in 495 of our reports, across 33 regions and countries.
Named as a key player in 495 of our reports, across 33 regions and countries.
2023–2033 CAGR · estimates
Australia 15
Brazil 15
Canada 15
China 15
Ecuador 15
Egypt 15
France 15
Germany 15
Hong Kong 15
India 15
Italy 15
Japan 15
Kenya 15
Malaysia 15
Mexico 15
New Zealand 15
Philippines 15
Russia 15
Saudi Arabia 15
Singapore 15
South Africa 15
Spain 15
Thailand 15
UAE 15
UK 15
US 15| Market | Category | World 2023 | CAGR |
|---|---|---|---|
| Dietary Supplements | OTC & Nutraceuticals | $308 Bn | 6.2% |
| Over The Counter (OTC) Drugs | OTC & Nutraceuticals | $178 Bn | 4.7% |
| Gastrointestinal Drugs | Pharmaceuticals | $54 Bn | 4.6% |
| Over The Counter (OTC) Analgesics | OTC & Nutraceuticals | $22 Bn | 3.4% |
| Over The Counter (OTC) Medications for Cough, Cold & Flu Drugs | OTC & Nutraceuticals | $14.5 Bn | 4.1% |
| Bone & Joint Health Supplements | OTC & Nutraceuticals | $12 Bn | 6.4% |
| Diabetic Retinopathy Drugs | Pharmaceuticals | $10.8 Bn | 6% |
| Over The Counter (OTC) Gastrointestinal Drugs | OTC & Nutraceuticals | $5.6 Bn | 3.9% |
| Digital Biomarkers | Digital Health | $4.4 Bn | 35.5% |
| Over The Counter (OTC) Ophthalmic Drugs | OTC & Nutraceuticals | $3.6 Bn | 4.5% |
| Osteoporosis Supplements | OTC & Nutraceuticals | $3.1 Bn | 6.5% |
| Anthelmintic Drug | OTC & Nutraceuticals | – | – |
| Anticoagulants | Pharmaceuticals | – | – |
| Antipyretics OTC | OTC & Nutraceuticals | – | – |
| Immune Health Supplement | OTC & Nutraceuticals | – | – |
Named as key players in the same markets as Bayer AG (number of shared markets).
GSK PLC6 shared markets
Johnson & Johnson6 shared markets
Novartis AG5 shared markets
Pfizer Inc.5 shared markets
Sanofi5 shared markets
Reckitt Benckiser Group PLC4 shared markets
AbbVie Inc.3 shared markets
Amway3 shared markets